Was this an infectious abscess, or something less common?
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.12788/jfp.0634 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Janus Kinase-Inhibitors in Ulcerative Colitis.
J Clin Med
November 2024
Gastroenterology Unit, Department of Systems Medicine, University "Tor Vergata" of Rome, 00133 Rome, Italy.
Janus kinase-inhibitors (JAK-i) have recently been approved for treating patients with Ulcerative Colitis (); therefore, further information is needed, particularly regarding efficacy and safety. To provide a comprehensive review regarding the efficacy and safety of currently available JAK-i in UC. The PubMed and Scopus databases were considered, searching for 'JAK', 'JAK-inhibitor', 'Janus Kinases', 'Tofacitinib', 'Filgotinib', 'Upadacitinib', individually or in combination with 'IBD', 'Ulcerative Colitis', 'safety', 'efficacy', 'study' and 'trial'.
View Article and Find Full Text PDFDupilumab-Associated Bilateral Conjunctival Papillomas and Corneal Perforation.
Cornea
February 2025
Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Purpose: We report a unique case of significant human papillomavirus-associated conjunctival papillomas and severe corneal ulceration leading to corneal perforation in a patient treated with dupilumab for atopic dermatitis.
Methods: This study is a case report and literature review of severe corneal side effects related to dupilumab.
Results: A 27-year-old man with severe atopic dermatitis and no ocular history was administered dupilumab 300 mg via subcutaneous injections every 2 weeks with an excellent response.
Game changer: How Janus kinase inhibitors are reshaping the landscape of ulcerative colitis management.
World J Gastroenterol
September 2024
Department of Nursing, Faculty of Health Sciences, University of Granada, Granada 18004, Spain.
Recent advancements in the treatment landscape of ulcerative colitis (UC) have ushered in a new era of possibilities, particularly with the introduction of Janus kinase (JAK)-signal transducer and activator of transcription inhibitors. These novel agents offer a paradigm shift in UC management by targeting key signaling pathways involved in inflammatory processes. With approved JAK inhibitors (JAKis), such as tofacitinib, filgotinib, and upadacitinib, clinicians now have powerful tools to modulate immune responses and gene expression, potentially revolutionizing the treatment algorithm for UC.
View Article and Find Full Text PDFAGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review.
Gastroenterology
November 2024
Division of Gastroenterology, Chinese University of Hong Kong, Hong Kong Special Administrative Region, The People's Republic of China.
Description: The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best Practice Advice on the integration of potassium-competitive acid blockers (P-CABs) in the clinical management of foregut disorders, specifically including gastroesophageal reflux disease, Helicobacter pylori infection, and peptic ulcer disease.
Methods: This expert review was commissioned and approved by the AGA Institute Governing Board and CPU Committee to provide timely guidance on a topic of high clinical importance to the AGA membership. This CPU expert review underwent internal peer review by the CPU Committee and external peer review through the standard procedures of Gastroenterology.
Physicochemical characterization of novel okra mucilage/hyaluronic acid-based oral disintegrating films for functional food applications.
Int J Biol Macromol
October 2024
Department of Applied Chemistry, Delhi Technological University, Bawana Road, Delhi 110 042, India. Electronic address:
Oral disintegrating films (ODFs) offer a patient-friendly approach with enhanced convenience and rapid onset of action over various health benefits. ODFs are fabricated for geriatric, pediatric, and individuals facing swallowing challenges. The present work aims to fabricate and characterize ODFs mainly composed of okra mucilage (OM), hyaluronic acid (HA), vitamin-C-loaded bioactive glass nanoparticles (VBG NPs), and clove essential oil.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!